OpenAI CEO Sam Altman is under fire for suggesting that artificial intelligence will upend societal norms after President Trump made a huge announcement on AI.

The CEO of OpenAI, Sam Altman took to his social media account on X (formerly Twitter) to share his thoughts about a letter of inquiry he received from Senators Elizabeth Warren and Michael Bennet. The letter raised questions about the motivations behind his donation to the incoming president’s inaugural fund.

Meta, Apple, Google and other tech companies have been named in a letter penned by Democratic lawmakers, accusing them of cozying up to President-elect Trump.

OpenAI CEO and co-founder Sam Altman clapped back at two Democratic senators’ inquiry into his $1 million personal donation to President-elect Trump’s inaugural fund, quipping Friday

WIth one foot out the White House door, the Biden administration issued 2 documents Musk is now using in his battle to break up OpenAI and Microsoft.

Chinese start-up DeepSeek is as powerful as ChatGPT and purportedly uses much less computing power. Will this competition spur US companies to greater things?

Chinese AI lab DeepSeek released two new AI models this month. Their limited use of resources to achieve extraordinary results is making the world take notice.

Steve Bannon, the former Trump aide and Maga guru, called Musk “out of control”, saying he “should not reverse what the president’s already talked about”. It seemed like the first hint of a long-predicted wedge between the leader of the free world and the world’s richest man.

WIth one foot out the White House door, the Biden administration issued 2 documents Musk is now using in his battle to break up OpenAI and Microsoft.

But with President Donald Trump recently announcing $500 billion of investment in AI infrastructure with The Stargate Project, a figure which makes the UK’s £14 billion bid to be a tech superpower look teeny, many think we really need to take Hawking’s warning seriously.

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.